Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

NCT03778346 is registered in ClinicalTrials.gov with The Sixth Affiliated Hospital of Wenzhou Medical University as lead sponsor.

NCT NCT03778346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03778346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells
Lead sponsor
The Sixth Affiliated Hospital of Wenzhou Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
November 15, 2018
Completion date
December 31, 2022
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rrmm